Last reviewed · How we verify
Multiple endocrine adenomas
Approved treatments
- Protonix · Generic (originally Byk Gulden/Altana/Nycomed)
Irreversibly inhibits the gastric proton pump (H+/K+ ATPase), suppressing stomach acid secretion. - Pantoprazole Sodium · Pfizer
Pantoprazole suppresses gastric acid by covalently binding the (H+, K+)-ATPase enzyme at parietal cells. - Aciphex · University of Utah
- Tagamet
- Aciphex · Waylis
Aciphex works by irreversibly inhibiting the potassium-transporting ATPase enzyme in the stomach lining, reducing acid production. - Rabeprazol · Janssen-Cilag, S.A.
- Pantoprazol · Northern Orthopaedic Division, Denmark
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Multiple endocrine adenomas patent landscape — cliff calendar, originator estates, attackable patents
- Multiple endocrine adenomas treatment landscape brief
- Multiple endocrine adenomas treatment updates RSS
Frequently asked questions about Multiple endocrine adenomas
What drugs treat Multiple endocrine adenomas?
Tracked treatments include Protonix, Pantoprazole Sodium, Aciphex, Tagamet, Rabeprazol, Pantoprazol.
What is the treatment for Multiple endocrine adenomas?
Standard treatment for Multiple endocrine adenomas includes Protonix, Pantoprazole Sodium, Aciphex, Tagamet, Rabeprazol. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Multiple endocrine adenomas patent cliff · Multiple endocrine adenomas CI report
- Treatment: Protonix · Generic (originally Byk Gulden/Altana/Nycomed)
- Treatment: Pantoprazole Sodium · Pfizer
- Treatment: Aciphex · University of Utah
- Treatment: Tagamet
- Treatment: Aciphex · Waylis
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing